Absci appoints Andreas Busch as Chief Innovation Officer; CTO Matthew Weinstock transitions to consultant

Absci Corp

Andreas Busch resigns from Board on Sept 30 to become Chief Innovation Officer effective Oct 4, 2022.
Former CTO Matthew Weinstock to serve as consultant after Oct 4; receives 12-month base salary severance, COBRA reimbursement, and $145,125 prorated bonus.
Dr. Busch brings R&D expertise from Sanofi, Bayer, Shire; led over 10 drugs to FDA approval.
As Chief Innovation Officer, Dr. Busch will lead R&D, technical operations, and internal/partner programs.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andreas Busch

Chief Innovation Officer

ABSI · Absci Corp

Filed: October 4, 2022, 7:59 PM ET

effective immediately upon his appointment as the Company's Chief Innovation Officer

Departed

Andreas Busch

Director

ABSI · Absci Corp

Effective: 2022-09-30
Filed: October 4, 2022, 7:59 PM ET

he would resign from the Company's Board of Directors

Departed

Matthew Weinstock

Chief Technology Officer

ABSI · Absci Corp

Effective: 2022-10-04
Filed: October 4, 2022, 7:59 PM ET

Matthew Weinstock, Ph.D., the Company's Chief Technology Officer, will transition into a consultant role on October 4, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.7

Andreas Busch was appointed as Chief Innovation Officer at Absci Corp.

Action: appointed
Role: Chief Innovation Officer

Exact text from the filing

effective immediately upon his appointment as the Company's Chief Innovation Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Andreas Busch resigned as Director at Absci Corp.

Action: resigned
Role: Director

Exact text from the filing

he would resign from the Company's Board of Directors

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Weinstock changed role as Chief Technology Officer at Absci Corp.

Action: transitioned to consultant
Role: Chief Technology Officer

Exact text from the filing

Matthew Weinstock, Ph.D., the Company's Chief Technology Officer, will transition into a consultant role on October 4, 2022.

View on SEC.gov

Absci Corp filing history →

Source: SEC EDGAR

accession 0001628280-22-025942

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.